JP6422163B2 - ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長 - Google Patents

ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長 Download PDF

Info

Publication number
JP6422163B2
JP6422163B2 JP2015520531A JP2015520531A JP6422163B2 JP 6422163 B2 JP6422163 B2 JP 6422163B2 JP 2015520531 A JP2015520531 A JP 2015520531A JP 2015520531 A JP2015520531 A JP 2015520531A JP 6422163 B2 JP6422163 B2 JP 6422163B2
Authority
JP
Japan
Prior art keywords
certain embodiments
cells
relates
aforementioned compounds
urolithin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015520531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523362A5 (cg-RX-API-DMAC7.html
JP2015523362A (ja
Inventor
エル リンシュ，クリストファー
エル リンシュ，クリストファー
ブランコ−ボーズ，ウィリアム
シュナイダー，ベルナール
ムーシルー，ローレン
リュ，ドンニョル
アンドルー，ペネロプ
オーウェル，ジョアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazentis SA
Original Assignee
Amazentis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6422163(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amazentis SA filed Critical Amazentis SA
Publication of JP2015523362A publication Critical patent/JP2015523362A/ja
Publication of JP2015523362A5 publication Critical patent/JP2015523362A5/ja
Application granted granted Critical
Publication of JP6422163B2 publication Critical patent/JP6422163B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
JP2015520531A 2012-06-27 2013-06-27 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長 Active JP6422163B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261665137P 2012-06-27 2012-06-27
US61/665,137 2012-06-27
US201261712886P 2012-10-12 2012-10-12
US61/712,886 2012-10-12
US201361791137P 2013-03-15 2013-03-15
US61/791,137 2013-03-15
PCT/US2013/048310 WO2014004902A2 (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018140453A Division JP6879980B2 (ja) 2012-06-27 2018-07-26 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Publications (3)

Publication Number Publication Date
JP2015523362A JP2015523362A (ja) 2015-08-13
JP2015523362A5 JP2015523362A5 (cg-RX-API-DMAC7.html) 2016-10-06
JP6422163B2 true JP6422163B2 (ja) 2018-11-14

Family

ID=48782652

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015520531A Active JP6422163B2 (ja) 2012-06-27 2013-06-27 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2018140453A Active JP6879980B2 (ja) 2012-06-27 2018-07-26 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2021077856A Active JP7339296B2 (ja) 2012-06-27 2021-04-30 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2023097670A Pending JP2023107934A (ja) 2012-06-27 2023-06-14 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2025135511A Pending JP2025161884A (ja) 2012-06-27 2025-08-15 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018140453A Active JP6879980B2 (ja) 2012-06-27 2018-07-26 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2021077856A Active JP7339296B2 (ja) 2012-06-27 2021-04-30 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2023097670A Pending JP2023107934A (ja) 2012-06-27 2023-06-14 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP2025135511A Pending JP2025161884A (ja) 2012-06-27 2025-08-15 ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Country Status (16)

Country Link
US (10) US11020373B2 (cg-RX-API-DMAC7.html)
EP (3) EP4566677A3 (cg-RX-API-DMAC7.html)
JP (5) JP6422163B2 (cg-RX-API-DMAC7.html)
KR (4) KR102163091B1 (cg-RX-API-DMAC7.html)
CN (2) CN105142632B (cg-RX-API-DMAC7.html)
AR (1) AR091604A1 (cg-RX-API-DMAC7.html)
AU (6) AU2013284419A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014032809A8 (cg-RX-API-DMAC7.html)
CA (2) CA2877718C (cg-RX-API-DMAC7.html)
DK (1) DK4233858T3 (cg-RX-API-DMAC7.html)
ES (2) ES3032009T3 (cg-RX-API-DMAC7.html)
MX (3) MX393128B (cg-RX-API-DMAC7.html)
PL (1) PL4233858T3 (cg-RX-API-DMAC7.html)
PT (2) PT2866804T (cg-RX-API-DMAC7.html)
SG (3) SG11201408539UA (cg-RX-API-DMAC7.html)
WO (1) WO2014004902A2 (cg-RX-API-DMAC7.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020373B2 (en) * 2012-06-27 2021-06-01 Amazentis Sa Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
EP2945622B1 (en) * 2013-01-18 2022-11-30 Mans, Jean-Pierre Composition comprising urolithin b and testosterone, leucine and/or creatine for muscle growth
US20160220609A1 (en) * 2013-09-09 2016-08-04 Natreon, Inc. Regulation of steroidogenic activity by using purified shilajit
EP2862568A1 (en) * 2013-10-15 2015-04-22 Centre National de la Recherche Scientifique (CNRS) Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201413228D0 (en) * 2014-07-25 2014-09-10 Nugerontix Ltd Polyphenol compositions
CN107427488A (zh) * 2014-12-19 2017-12-01 光环生命科学有限公司 鞣花酸二水合物在食品和保健品中的用途
EP3284734B1 (en) * 2015-04-13 2021-12-01 Sumitomo Seika Chemicals Co., Ltd. Method for producing 2-halogenated benzoic acids
JP6740548B2 (ja) * 2015-05-15 2020-08-19 公立大学法人岡山県立大学 ウロリチン類を含有する育毛剤、及び、ウロリチン類を含有する５αレダクターゼ活性阻害剤
JP2017014154A (ja) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
JP6799767B2 (ja) * 2015-07-07 2020-12-16 公立大学法人岡山県立大学 ウロリチン類を含有するメラニン産生抑制剤
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
RU2751638C2 (ru) * 2015-12-24 2021-07-15 Амазентис Са Композиции, содержащие никотинамидрибозид и уролитин
JP6791478B2 (ja) * 2016-05-26 2020-11-25 株式会社ダイセル ウロリチン類を含有するアンジオテンシン変換酵素阻害剤
JP2017210444A (ja) * 2016-05-26 2017-11-30 株式会社ダイセル ウロリチン類を含有するリパーゼ阻害剤
US10981928B2 (en) * 2016-06-29 2021-04-20 Halo Life Science, Llc Methods of making low odor choline salts of an organic compound
US10774328B2 (en) 2016-07-11 2020-09-15 University Of North Texas Health Science Center At Fort Worth Treatment for glaucoma and other eye diseases
US11634686B2 (en) 2016-11-01 2023-04-25 Jian Feng Method of producing naive pluripotent stem cells
EP3354645A1 (en) 2017-01-26 2018-08-01 Patheon Austria GmbH & Co KG Process for preparing urolithins
CN110709077A (zh) 2017-03-08 2020-01-17 阿马曾提斯公司 皮肤治疗方法
EP4566601A3 (en) 2017-03-08 2025-09-03 Amazentis SA Methods for improving mitophagy in subjects
WO2018162650A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Methods for improving mitophagy in subjects
JP2019097566A (ja) * 2017-12-07 2019-06-24 大正製薬株式会社 体内時計調整用組成物
BR112020009765A2 (pt) * 2017-12-20 2020-11-03 Société des Produits Nestlé S.A. composições e métodos que usam uma combinação de indutor de autofagia e alto teor de proteína para indução de autofagia
WO2019121855A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using high protein for induction of autophagy
JP2022500347A (ja) * 2018-02-19 2022-01-04 ナトレオン，インコーポレイテッド 認知能又は認知機能を改善するためのウロリチンａ及びｂの相乗的組み合わせ
WO2019163437A1 (ja) 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
AU2019227733B2 (en) * 2018-02-27 2024-08-01 Amazentis Sa Process-scale synthesis of urolithin A
WO2019187918A1 (ja) * 2018-03-29 2019-10-03 国立大学法人 琉球大学 分化コントロール化合物を用いて造腫瘍性をもつおそれのある未分化ｉＰＳ細胞等の混入を除去する方法
JP7557374B2 (ja) 2018-04-30 2024-09-27 アマゼンティス エスアー 免疫増強剤としてのウロリチンａ
JP2021523942A (ja) 2018-05-15 2021-09-09 ユニバーシティ・オブ・ルイスビル・リサーチ・ファウンデーション・インコーポレイテッドＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｌｏｕｉｓｖｉｌｌｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃ． 療法における使用のためのウロリシンａおよびその誘導体
WO2019236775A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
EP3801587A4 (en) * 2018-06-05 2022-08-10 Flagship Pioneering Innovations V, Inc. ACYLATED CATECHIN POLYPHENOLS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
CN108676013B (zh) * 2018-06-25 2021-01-01 中国医学科学院医药生物技术研究所 具有自噬激活活性的黄醇酮类化合物、其制备方法及其制药应用
CN109316478A (zh) * 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品
PL245399B1 (pl) 2018-11-29 2024-07-15 Univ Warszawski Medyczny Kompozycja farmaceutyczna zawierająca urolitynę A lub jej pochodną do zastosowania zewnętrznego miejscowego w leczeniu, hamowaniu i zapobieganiu chorobom skóry i błon śluzowych o podłożu zapalnym
WO2020148445A1 (en) * 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
CN110066284B (zh) * 2019-02-01 2021-06-04 贵阳倍隆生物科技有限公司 一种一锅法合成鞣花酸的方法
CN110229167B (zh) * 2019-05-22 2020-11-24 珠海萱嘉君行健康产业发展有限公司 一种利用五倍子制备鞣花酸的方法、制得的鞣花酸及其应用
CN111995610A (zh) * 2019-05-27 2020-11-27 首都医科大学 一种尿石素类化合物用于治疗胶质母细胞瘤药物的应用
US20200397807A1 (en) * 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
GB201915191D0 (en) 2019-10-21 2019-12-04 Floratek Gmbh Novel heterocyclic compounds
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
US20230048350A1 (en) * 2019-11-27 2023-02-16 Societe Des Produits Nestle S.A. Benzocoumarin ampk activator compounds, compositions, methods and uses thereof
CN114760996A (zh) * 2019-11-27 2022-07-15 雀巢产品有限公司 与间接ampk活化剂化合物组合的直接ampk活化剂化合物、组合物、方法和其用途
CN113018305A (zh) * 2019-12-24 2021-06-25 兰州大学 一种化合物在制备治疗阿尔兹海默症药物中的应用
CA3168493A1 (en) * 2020-02-20 2021-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors
US20240000753A1 (en) * 2020-07-17 2024-01-04 The Trustees Of Columbia University In The City Of New York Methods and compositions to increase lifespan and healthspan by mimicking the effects of time-restricted feeding
CN111983058B (zh) * 2020-07-30 2023-06-23 云南中医药大学 中药抗非酒精性脂肪肝活性物质的筛选方法
US20220071952A1 (en) * 2020-09-04 2022-03-10 Natreon, Inc. Methods of treating and preventing hepatotoxicity
CA3188397A1 (en) 2020-09-25 2022-03-31 Anupama Dattatreya Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
KR20230153533A (ko) 2021-01-27 2023-11-06 반드리아 에스에이 유로리틴 유도체 및 이의 사용 방법
CN112716938A (zh) * 2021-02-25 2021-04-30 新疆医科大学 鞣花酸在制备缓解眼组织病变的药物中的用途
KR102677423B1 (ko) * 2021-09-17 2024-06-21 조선대학교산학협력단 망기페린을 포함하는 자가포식 활성화용 조성물
KR102690860B1 (ko) * 2021-10-13 2024-08-05 한국해양과학기술원 남극 진균 균주 Pleosporales sp. SF-7343 유래 대사화합물을 포함하는 염증질환 예방 또는 치료용 조성물
WO2023073079A1 (en) * 2021-10-28 2023-05-04 Société des Produits Nestlé S.A. Compositions and methods using a combination of nutrients to support cognition and emotional health in a mammal
WO2023161453A1 (en) 2022-02-24 2023-08-31 Amazentis Sa Uses of urolithins
WO2023180214A1 (en) 2022-03-22 2023-09-28 Amazentis Sa Compositions
EP4536212A2 (en) * 2022-06-06 2025-04-16 Amazentis SA Urolithins for improving cardiac function and health
EP4561556A2 (en) * 2022-07-27 2025-06-04 Vandria SA Therapeutic uses of urolithin derivatives
CN115433151A (zh) * 2022-09-02 2022-12-06 苏州大学 一种6，7，8-三羟基香豆素的制备方法
CN115581689B (zh) * 2022-10-17 2024-05-14 常州大学 尿石素b酰胺类衍生物的应用
GB202219317D0 (en) 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
CN116966188A (zh) * 2023-07-14 2023-10-31 天津医科大学总医院 丁香素在制备治疗和/或预防炎症性肠病药物中的应用
GB202312220D0 (en) 2023-08-09 2023-09-20 Amazentis Sa Formulation
WO2025076497A1 (en) * 2023-10-06 2025-04-10 Northeast Ohio Medical University Combination treatment of tau pathology
FR3153998A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d’iso-urolithine A sur une peau sensible
FR3153997A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine B sur une peau sensible
WO2025078645A1 (en) * 2023-10-13 2025-04-17 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
FR3153996A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine C sur une peau sensible
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
CN117771237B (zh) * 2024-02-27 2024-05-03 南昌医学院 一种松香烷型二萜化合物的用途和制备方法
WO2025194036A1 (en) * 2024-03-14 2025-09-18 Washington University Autophagy enhancers
WO2025224366A1 (en) 2024-04-26 2025-10-30 Amazentis Sa Immune health improvers
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations
CN119792272B (zh) * 2025-02-07 2025-10-03 陕西中鸿科瑞再生医学研究院有限公司 一种改善睡眠的组合物及其制备方法与制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6479103A (en) 1987-06-09 1989-03-24 Lion Corp External preparation
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US6440436B1 (en) 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
MX2008011013A (es) 2006-02-28 2008-10-23 Paloma Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades caracterizadas por proliferacion celular y angiogenesis.
WO2007127263A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Therapeutic uses of urolithins
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
US20100298249A1 (en) * 2007-05-11 2010-11-25 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
EP2155154A2 (fr) * 2007-05-11 2010-02-24 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
TW200929211A (en) 2007-12-17 2009-07-01 Etron Technology Inc Method of reducing current of memory in self-refreshing mode
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2009228303B2 (en) 2008-03-25 2015-08-13 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
WO2010118419A2 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
JP5385686B2 (ja) 2009-06-05 2014-01-08 サントリーホールディングス株式会社 血小板凝集抑制剤
EP2456772A4 (en) * 2009-07-24 2013-02-27 Amazentis Sa COMPOUNDS, COMPOSITIONS AND METHODS FOR CONSERVING HEALTH HEALTH IN NEURODEEGENERATIVE DISEASES
CA2822898C (en) * 2010-12-23 2021-01-05 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
US20130324595A1 (en) 2011-02-22 2013-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
US11020373B2 (en) 2012-06-27 2021-06-01 Amazentis Sa Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
RU2751638C2 (ru) 2015-12-24 2021-07-15 Амазентис Са Композиции, содержащие никотинамидрибозид и уролитин

Also Published As

Publication number Publication date
KR102163091B1 (ko) 2020-10-08
US20200397748A1 (en) 2020-12-24
JP6879980B2 (ja) 2021-06-02
KR20210128511A (ko) 2021-10-26
JP2015523362A (ja) 2015-08-13
AU2013284419A1 (en) 2015-02-12
EP2866804A2 (en) 2015-05-06
AU2022200876A1 (en) 2022-03-03
AU2020200420B2 (en) 2021-11-11
US20250228817A1 (en) 2025-07-17
US20250375415A1 (en) 2025-12-11
PT2866804T (pt) 2023-12-18
CN105142632B (zh) 2020-01-07
EP4566677A2 (en) 2025-06-11
JP7339296B2 (ja) 2023-09-05
AU2018200791A1 (en) 2018-02-22
CA2877718C (en) 2021-10-12
US20180015069A1 (en) 2018-01-18
CN105142632A (zh) 2015-12-09
EP4233858B1 (en) 2025-02-12
PT4233858T (pt) 2025-05-15
BR112014032809A8 (pt) 2021-06-22
KR20230116091A (ko) 2023-08-03
AU2024259763A1 (en) 2024-11-21
CN110934863A (zh) 2020-03-31
DK4233858T3 (da) 2025-05-12
MX378354B (es) 2025-03-10
US20210353591A1 (en) 2021-11-18
MX393128B (es) 2025-03-24
KR20150036224A (ko) 2015-04-07
US9962366B2 (en) 2018-05-08
EP4233858A1 (en) 2023-08-30
US11931336B2 (en) 2024-03-19
EP4566677A3 (en) 2025-09-03
PL4233858T3 (pl) 2025-06-09
KR102317160B1 (ko) 2021-10-25
US20230233523A1 (en) 2023-07-27
AU2020200420A1 (en) 2020-03-05
US20250228816A1 (en) 2025-07-17
AU2018202407A1 (en) 2018-04-26
US20140018415A1 (en) 2014-01-16
SG10202106329TA (en) 2021-07-29
ES3032009T3 (en) 2025-07-14
US11020373B2 (en) 2021-06-01
JP2018184455A (ja) 2018-11-22
SG11201408539UA (en) 2015-01-29
JP2021119180A (ja) 2021-08-12
AU2022200876B2 (en) 2024-08-15
CA3127211A1 (en) 2014-01-03
AU2018202407B2 (en) 2019-11-21
JP2025161884A (ja) 2025-10-24
AR091604A1 (es) 2015-02-18
US20160000753A1 (en) 2016-01-07
MX2014016044A (es) 2015-05-12
KR20200116176A (ko) 2020-10-08
WO2014004902A3 (en) 2014-03-06
MX2022007264A (es) 2022-07-13
US11931335B2 (en) 2024-03-19
BR112014032809A2 (pt) 2017-06-27
AU2018200791B2 (en) 2019-10-31
MX2020008468A (es) 2022-06-14
JP2023107934A (ja) 2023-08-03
WO2014004902A2 (en) 2014-01-03
SG10201610798QA (en) 2017-02-27
CA2877718A1 (en) 2014-01-03
ES2968368T3 (es) 2024-05-09
EP2866804B1 (en) 2023-09-13
US20230390238A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
JP7339296B2 (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181012

R150 Certificate of patent or registration of utility model

Ref document number: 6422163

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250